Atlas Brown Inc. Has $279,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Atlas Brown Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 536 shares of the medical research company’s stock after selling 44 shares during the quarter. Atlas Brown Inc.’s holdings in Thermo Fisher Scientific were worth $279,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. Jacobs & Co. CA grew its stake in shares of Thermo Fisher Scientific by 10.7% during the fourth quarter. Jacobs & Co. CA now owns 15,206 shares of the medical research company’s stock worth $7,910,000 after purchasing an additional 1,473 shares during the period. CCM Investment Advisers LLC grew its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. CCM Investment Advisers LLC now owns 31,921 shares of the medical research company’s stock worth $16,606,000 after buying an additional 2,822 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Thermo Fisher Scientific by 0.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 126,603 shares of the medical research company’s stock valued at $65,863,000 after acquiring an additional 887 shares during the last quarter. Hudson Valley Investment Advisors Inc. ADV boosted its stake in Thermo Fisher Scientific by 1.3% during the 4th quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,331 shares of the medical research company’s stock worth $10,577,000 after acquiring an additional 268 shares during the last quarter. Finally, Legacy Private Trust Co. increased its stake in Thermo Fisher Scientific by 1.8% in the fourth quarter. Legacy Private Trust Co. now owns 11,912 shares of the medical research company’s stock valued at $6,197,000 after purchasing an additional 205 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $1.26 during trading hours on Friday, reaching $543.67. 2,305,858 shares of the stock were exchanged, compared to its average volume of 1,858,875. The stock’s fifty day simple moving average is $530.21 and its 200 day simple moving average is $568.07. The firm has a market capitalization of $207.95 billion, a price-to-earnings ratio of 34.09, a P/E/G ratio of 3.54 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.69 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This trade represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on TMO shares. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Bank of America cut their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a report on Friday, December 13th. TD Cowen increased their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $650.52.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.